WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Active:	Yes
Cancer Type:	Lymphoma Non-Hodgkin Lymphoma	NCT ID:	NCT05678998
Trial Phases:	Phase I	Protocol IDs:	WTX-330x2101 (primary) NCI-2023-00670
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Werewolf Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05678998

Summary

A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a
monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

Objectives

This is a first-in-human, Phase 1, open-label, multicenter study to evaluate the safety,
tolerability and preliminary efficacy of WTX-330, a conditionally-activated IL-12
prodrug, when administered as a monotherapy to patients with advanced or metastatic solid
tumors or non-Hodgkin lymphoma. Dose escalation will be conducted in patients with
advanced and/or metastatic solid tumors who are refractory to all standard of care
therapies. Dose expansion will be conducted in two arms: Arm A will enroll patients with
indications for which a checkpoint inhibitor (CPI) is indicated/approved who demonstrate
primary or secondary resistance to an anti-PD(L)1 treatment regimen, and Arm B will
enroll patients with tumor types for which CPI therapy is not indicated/approved.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.